Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.

Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.

The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.

Retinoids are effective for various skin conditions and hair loss but have serious side effects, so low doses are recommended.

Botulinum toxin is effective for various skin conditions, but more research and awareness of side effects are needed.

The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.

The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.

Off-label drug use can be risky but sometimes beneficial when standard treatments fail.

Some off-label treatments increase hair density, but long-term safety unknown.

Most off-label drug prescriptions in Saudi Arabia are for adults with depression and diabetes.

Botulinum toxin shows promise for various skin conditions but requires more research for confirmation and standardized use.

GSK-36 downregulation with UTMD improves plaque stability in atherosclerosis treatment.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Clinicians should use social and prescription data to track trends in performance-enhancing drug use.

Minoxidil can help increase facial hair growth.

Flibanserin may help improve sexual symptoms in various conditions beyond its approved use.

Photobiomodulation therapy may help treat hair loss in people with darker skin, but more research is needed.

Some medications can help increase sexual desire and function in women.

New medications are improving depression treatment, emphasizing accurate diagnosis and chronic care.

Minoxidil is less effective on eyebrows and eyelashes than scalp hair because these areas have lower enzyme activity needed to activate the drug.

Health warnings and public health actions led to a significant drop in flutamide prescriptions for women, but off-label use still continues.

Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.

Hair loss can be managed with treatments like minoxidil, finasteride, and others, but there are still gaps in effectiveness and off-label usage is increasing.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Taking spironolactone doesn't increase the chance of breast cancer coming back.